[228] Other devices to aid vaccine administration such as intradermal needle adaptors have also been developed for use in the field. Vaccine candidates in clinical development: Phase I safety and ...

The collaboration could potentially lead to the first approved needle-free intradermal delivery of a botulinum toxin product. In other company developments, Revance Therapeutics is in discussions ...

"We are excited to partner with Revance to further clinical development of our unique program, using our Xyngari™ product for a needle-free, intradermal delivery of a botulinum toxin, like ...

Detailed price information for Dermata Therapeutics Inc WT (DRMAW-Q) from The Globe and Mail including charting and trades.